Prof. M. Kürşat Gökcan, MD Otolaryngology – Head and Neck Surgery
TREN
Appointments: +90 312 321 07 07

Thyroid cancer surgery

With the right treatment, thyroid cancer has a high chance of cure. This article covers the types of thyroid cancer, how the extent of surgery is decided, how the nerves and parathyroid glands are protected during the operation, and radioactive iodine treatment.

Prof. M. Kürşat Gökcan, MD · Last updated: November 2026

Thyroid cancer is uncommon compared with other cancers. According to the American Cancer Society’s 2026 estimates, the United States sees about 45,000 cases of thyroid cancer a year, against roughly 325,000 cases of breast cancer and 159,000 of colorectal cancer. It also differs from other cancers in its low death rate: about 2,300 deaths are expected for some 45,000 new cases a year. Thyroid cancer is treated mainly with surgery and radioactive iodine, and the chance of success is high.

What causes thyroid cancer?

The main known risk factors are exposure to radiation, a family history of thyroid cancer, and age over 40. These account for only a small share of patients, however; for most, we cannot identify a specific cause. Radiation exposure in childhood in particular increases susceptibility. In the 1960s, before the long-term harms of radiation were well understood, it was widely used for purposes ranging from acne treatment to shrinking the tonsils and adenoids. It later became clear that all of these treatments raised the risk of thyroid cancer in later life. By contrast, the X-ray doses used in routine chest films, dental films and mammograms have not been shown to increase the risk.

Thyroid cancer is also more frequent in regions exposed to radioactive iodine fallout after nuclear accidents. Sadly, children are affected most, and most quickly. In adults too, the risk remains raised even 30–40 years after exposure.

How is thyroid cancer diagnosed?

Thyroid cancer is diagnosed with ultrasound and fine-needle aspiration biopsy, as described in the article on thyroid nodules. Ultrasound-guided fine-needle biopsy is the gold standard. The needle is very thin, so there is no risk of cancer cells being spread into the neck or made to multiply.

What types of cancer occur in the thyroid?

Papillary thyroid cancer

The most common type, making up about 80–85% of all thyroid cancers. It can occur at almost any age, from childhood to old age. It tends to grow slowly and usually spreads to the lymph nodes of the neck. Unlike many cancers, it can be treated very successfully with the right treatment even when it has spread to the lymph nodes.

Follicular thyroid cancer

Seen mostly in middle and older age, it makes up about 10% of all thyroid cancers. It can spread to lymph nodes, but it can also spread through the bloodstream to distant organs such as the lungs and bones.

Medullary thyroid cancer

Unlike the other types, it arises not from the cells that make thyroid hormone but from the parafollicular cells that make calcitonin. It makes up about 3–5% of all thyroid cancers. It can run in families and may occur together with other endocrine diseases or tumours; the RET proto-oncogene is tested to detect familial disease. It can spread to the neck lymph nodes and to distant organs. Surgery is the mainstay of treatment; targeted drug therapies are available for advanced disease.

Anaplastic thyroid cancer

A rare type, 1–2% of all thyroid cancers, and one of the most aggressive cancers in the human body. Its treatment has nevertheless advanced considerably in recent years: in patients whose tumour carries the BRAF V600E mutation, new-generation targeted drugs (dabrafenib and trametinib), with immunotherapy (pembrolizumab) added, make some previously inoperable tumours operable and extend survival. Molecular testing of the tumour as soon as the diagnosis is made is therefore very important.

How is thyroid cancer treated?

Surgery

Surgery is the most effective and the first-choice treatment for all types of thyroid cancer. The extent of the operation depends on the size of the tumour, whether it extends beyond the thyroid, and whether it has spread to the lymph nodes:

  • Lobectomy (removal of half of the thyroid): The operation recommended in current guidelines for low-risk cancers of 2 cm or less that are confined to one lobe, have not grown beyond the thyroid and have not spread to lymph nodes.
  • Lobectomy or total thyroidectomy: For tumours between 2 and 4 cm confined to one lobe, the choice depends on the features of the tumour, whether there are nodules in the other lobe, and the patient’s preference.
  • Total thyroidectomy (removal of the whole thyroid): For cancers larger than 4 cm, those extending beyond the thyroid, or those that have spread to lymph nodes or distant organs; the involved lymph node compartments are also cleared (central neck dissection and neck dissection).

Sometimes, even when there is no evident disease in the lymph nodes at diagnosis, your surgeon may recommend, in selected patients, clearing the “central compartment” around the thyroid as a precaution against recurrence. This procedure, called elective central neck dissection, removes the lymph nodes in the area where the cancer is likely to spread first; it aims both to lower the chance of recurrence there and to stage the disease accurately.

For low-risk papillary cancers smaller than 1 cm and confined to the thyroid, active surveillance with regular ultrasound instead of immediate surgery is also an accepted option in current guidelines for carefully selected patients.

Patients whose first operation was inadequate, or whose disease recurs in the lymph nodes, need further surgery. We recommend that these operations, known as recurrent or revision thyroid surgery, be performed under intraoperative nerve monitoring by surgeons who specialise in the field.

After total thyroidectomy, patients must take thyroid hormone medication every morning for life. After lobectomy, some patients do not need medication. For surgical technique, risks and other details, see the articles on thyroid surgery and surgery for recurrent thyroid cancer.

Nerve monitoring and preservation of the parathyroid glands

The two most important risks of thyroid surgery are injury to the nerves that move the vocal folds and to the parathyroid glands, which regulate calcium in the blood. We use two technologies in our operations to protect these structures:

  • Intraoperative nerve monitoring: The location and function of the vocal fold nerves (the recurrent laryngeal nerves) are checked throughout the operation with electrical stimulation, making the nerve easier to find and protect.
  • Fluorescence imaging of the parathyroid glands (NIRAF and ICG): Near-infrared autofluorescence (NIRAF) helps to identify the parathyroid glands during surgery, and indocyanine green (ICG) angiography helps to assess their blood supply. The aim is to reduce the risk of low calcium after surgery.

Prof. M. Kürşat Gökcan is among the pioneers in Türkiye of nerve monitoring in thyroid surgery and of fluorescence imaging to preserve the parathyroid glands.

He trained in 2006–2007 with Dr. Gregory W. Randolph in the Division of Thyroid and Parathyroid Surgery at Massachusetts Eye and Ear Infirmary, Harvard Medical School; published a Turkish-language review of intraoperative recurrent laryngeal nerve monitoring in 2009; supervised a residency thesis on revision thyroid surgery under neural monitoring in 2016; and wrote the book chapter “Neuromonitoring in thyroid surgery” in 2021.

Radioactive iodine treatment

The thyroid is the only organ in the body that stores and uses iodine. Radioactively labelled iodine is therefore used to destroy any thyroid tissue or thyroid cancer cells that may remain after total thyroidectomy. Because other tissues do not take up radioactive iodine, its side effects are few. In patients who receive repeated or high-dose treatment, the most common side effect is a dry mouth caused by damage to the salivary glands. Patients who need repeated high-dose treatment also have a higher risk of developing a second cancer later. So although it is a targeted treatment with few side effects, it is not given to every patient and must be used judiciously.

Sources

  1. Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid 2025.
  2. American Cancer Society. Cancer Facts & Figures 2026.
  3. Hamidi S, Iyer PC, Dadu R, et al. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 2024.